title: Drug evaluation: Degarelix--a potential new therapy for prostate cancer.
abstract: Ferring Research Ltd and licensee Astellas Pharma Inc are developing the gonadotropin-releasing hormone antagonist degarelix as a potential subcutaneous treatment for prostate cancer.
authors.affiliation: Department of Urology, University of Lübeck Medical School, Ratzeburger Allee 160, 23538 Lübeck, Germany. doehn@medinf.mu-luebeck.de
authors.forename: Christian
authors.initials: C
authors.lastname: Doehn
authors.forename: Martin
authors.initials: M
authors.lastname: Sommerauer
authors.forename: Dieter
authors.initials: D
authors.lastname: Jocham
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D009842:Oligopeptides; C431566:acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; D007987:Gonadotropin-Releasing Hormone